Condition: Differentiated Thyroid Cancer · Pediatric Cancer · Cancer · Sponsor: Children's Hospital of Philadelphia
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.
This description comes directly from the study's public registry record.
Meghan Donnelly, MPH · 267-426-9343 · 23DT022@chop.edu
James Robinson · 215-590-2053 · robinsonj9@chop.edu
Always discuss trial participation with your own doctor first.
| The Unviersity of California, San Francisco (UCSF) | San Francisco, California, United States | Not Yet Recruiting |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| St. Jude Children's Research Hospital | Memphis, Tennessee, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Seattle Children's Hospital | Seattle, Washington, United States | Terminated |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06458036